bremelanotide

11/01/2019 - "Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder. "
11/01/2019 - "Women who completed the 24-week double-blind core phase of RECONNECT, composed of two parallel phase 3 trials (301 and 302) examining the safety and efficacy of bremelanotide compared with placebo in premenopausal women with hypoactive sexual desire disorder, could enroll in the 52-week open-label extension, provided they had not experienced serious adverse events during the core phase. "
11/01/2019 - "Two identical phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials (RECONNECT) evaluated the safety and efficacy of bremelanotide 1.75 mg administered subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder. "
11/01/2019 - "To evaluate the long-term safety and efficacy of bremelanotide as treatment for hypoactive sexual desire disorder in premenopausal women. "
11/01/2019 - "Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder."

01/01/2022 - "In Study A, 27 of 30 bremelanotide subjects (90.0%) completed the trial and exhibited a significantly greater reduction in body weight after 16 days versus placebo [least squares mean difference (95% CI), -1.3 (-1.9 to -0.8) kg; p < .0001]. "
01/01/2022 - "Significantly greater reduction of mean body weight occurred in twice-daily bremelanotide subjects versus placebo (1.7 vs. 0.9 kg, respectively, p < .001). "
01/01/2022 - "Results from two randomized controlled clinical trials examine the effects of bremelanotide's agonism at MC4R on caloric intake and body weight. "
01/01/2022 - "Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials."
01/01/2022 - "This report investigates efficacy of bremelanotide versus placebo according to prespecified subgroups (age, weight, body mass index [BMI], and bioavailable testosterone) in the RECONNECT studies. "

11/01/2007 - "Newer CNS-acting agents such as bremelanotide show significant promise in bringing to clinical practice a group of centrally acting agents to supplement the treatment of erectile dysfunction. "
01/01/2008 - "Bremelanotide can be an alternative treatment for erectile dysfunction with a potentially broad patient base. "
06/01/2003 - "Administration of PT-141 to normal men and to patients with erectile dysfunction resulted in a rapid dose-dependent increase in erectile activity. "
01/01/2008 - "We evaluated the safety and efficacy of intranasal bremelanotide in men with erectile dysfunction who did not respond to sildenafil. "
01/01/2008 - "A total of 342 married men (28 to 59 years old) with erectile dysfunction who did not respond to sildenafil were randomly assigned to receive 10 mg bremelanotide as an intranasal spray (group 1, 172) 45 minutes to 2 hours prior to sexual stimulation, or a similar regimen of placebo (group 2, 170). "

01/01/2023 - "Bremelanotide appears to be moderately safe and well-tolerated; the most common adverse reaction is nausea (40%). "
01/01/2022 - "Nausea was the most common reason for bremelanotide discontinuation. "
11/01/2019 - "Patients taking bremelanotide experienced more nausea, flushing, and headache (10% or more in both studies) compared with placebo. "
01/01/2022 - "The most common adverse events (AEs) were nausea (40.0% vs. 1.3%), flushing (20.3% vs. 1.3%), headache (11.3% vs. 1.9%), and injection site reactions (5.4 vs. 0.5), bremelanotide versus placebo groups, respectively, in the integrated double-blind portion of the phase 3 studies (N = 1247). "

11/01/2019 - "Patients taking bremelanotide experienced more nausea, flushing, and headache (10% or more in both studies) compared with placebo. "
01/01/2022 - "The most common adverse events (AEs) were nausea (40.0% vs. 1.3%), flushing (20.3% vs. 1.3%), headache (11.3% vs. 1.9%), and injection site reactions (5.4 vs. 0.5), bremelanotide versus placebo groups, respectively, in the integrated double-blind portion of the phase 3 studies (N = 1247). "